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Background: Bisphosphonates are an important class of antiresorptive drugs used in the treatment of metabolic
bone diseases. Recent studies have shown that nitrogen-containing bisphosphonates induced apoptosis in rabbit
osteoclasts and prevented prenylated small GTPase. However, whether bisphosphonates inhibit osteoclast
formation has not been determined. In the present study, we investigated the inhibitory effect of minodronate
and alendronate on the osteoclast formation and clarified the mechanism involved in a mouse macrophage-like
cell lines C7 and RAW264.7.
Results: It was found that minodronate and alendronate inhibited the osteoclast formation of C7 cells induced
by receptor activator of NF-κB ligand and macrophage colony stimulating factor, which are inhibited by the
suppression of geranylgeranyl pyrophosphate (GGPP) biosynthesis. It was also found that minodronate and
alendronate inhibited the osteoclast formation of RAW264.7 cells induced by receptor activator of NF-κB ligand.
Furthermore, minodronate and alendornate decreased phosphorylated extracellular signal-regulated kinase 1/2
(ERK1/2) and Akt; similarly, U0126, a mitogen protein kinase kinase 1/2 (MEK1/2) inhibitor, and LY294002, a
phosphatidylinositol 3-kinase (PI3K) inhibitor, inhibited osteoclast formation.
Conclusions: This indicates that minodronate and alendronate inhibit GGPP biosynthesis in the mevalonate
pathway and then signal transduction in the MEK/ERK and PI3K/Akt pathways, thereby inhibiting osteoclast
formation. These results suggest a novel effect of bisphosphonates that could be effective in the treatment of
bone metabolic diseases, such as osteoporosis.
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Osteoclasts are multinucleated cells responsible for bone
resorption. It is therefore critical to understand the regu-
latory mechanism of osteoclast formation and function
to develop an effective treatment for metabolic bone dis-
eases, such as osteoporosis [1]. Multinucleated osteo-
clasts are generated from hematopoietic precursor cells* Correspondence: nishida@phar.kindai.ac.jp
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stated.through the action of macrophage-colony stimulating
factor (M-CSF) and receptor activator of NF-κB ligand
(RANKL) [2-4]. These cytokines act on osteoclast pre-
cursor cells that express their receptors, c-fms and RANK,
respectively. These receptors transmit osteoclastogenic
signals through transcription-factor-activating intercellular
kinase cascades, such as mitogen-activated protein kinases
(MAPKs), phosphatidylinositol 3-kinase (PI3K)/Akt, and
c-Src; these transcription factors include NF-κB, c-Fos/
AP-1, and NFAT [5-7]. Consequently, it has been shown
that mice deficient in NF-κB, c-Fos, NFAT, M-CSF, c-fms,Ltd. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Minodronate and alendronate inhibited osteoclast formation in C7 cells. (A, B) Determination of the appropriate concentrations
of minodronate (A) and alendronate (B) that are not cytotoxic to C7 cells. Cells (5000 cells/well) were incubated in 96-well plates for 24 h and
then treated with various concentrations of minodronate and alendronate. After 12 days, cell viability was quantified by conducting WST-8 assays.
The results are representative of 5 independent experiments. *P < 0.01 compared to the controls. (C-F) Inhibition of osteoclast formation by
minodronate and alendronate. C7 cells were cultured for 12 days and then treated with 0.1, 0.25, or 0.5 μM minodronate (C, E) or 0.5, 1, or 2 μM
alendronate (D, F). Cells were cultured in the presence of 25 ng/mL RANKL plus 50 ng/mL M-CSF. Cultures were fed every 3 days by replacing
with 500 μL of fresh medium with or without minodronate, alendronate, RANKL, and M-CSF. Cultures were fixed and stained for TRAP-positive
multinucleated cells (C, D), and TRAP-positive cells (E, F) per well was counted. These results are representative of 5 independent experiments.
*P < 0.01 compared to 25 ng/mL RANKL plus 50 ng/mL M-CSF administration. (G, H) Inhibitory effect of minodronate and alendronate on RANKL
and M-CSF-induced CTR and cathepsin K mRNA expression. C7 cells were treated with minodronate (G) or alendronate (H) with 25 ng/mL RANKL
plus 50 ng/mL M-CSF for 12 days. Total RNA was extracted and the levels of CTR and cathepsin K mRNA expression were determined by real-time
PCR. The results are expressed as the ratio of treated to control samples after normalization to GAPDH mRNA levels. The results are representative
of 4 independent experiments. *P< 0.01 compared to 25 ng/mL RANKL plus 50 ng/mL M-CSF administration.
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lop osteopetrosis [8-11].
Nitrogen-containing bisphosphonates (N-BPs) are a class
of drugs used in the treatment of osteoporosis and diseases
associated with high bone turnover [12]. N-BPs have been
shown to prevent formation of farnesyl pyrophosphate
(FPP) and geranylgeranyl pyrophosphate (GGPP), through
inhibition of FPP synthase and GGPP synthase, both
enzymes in the mevalonate pathway [13-16]. A major effect
of these agents is promotion of apoptosis of mature osteo-
clasts. Recently, N-BPs have been reported to inhibit
osteoclast formation in vitro [17]. The mechanism of sup-
pression of osteoclast formation has also been reported to
involve the inhibition of GGPP biosynthesis. In addition,
although there is a report that N-BPs also induce the
inhibition of small GTPases prenylation [18], several
characteristics of osteoclast precursor cells remain un-
clear. In the present study, we investigated the mech-
anism by which minodronate and alendronate inhibit
osteoclast formation in the macrophage-like cell lines C7
and RAW264.7.Methods
Materials
Minodronate was supplied from Astellas Pharmaceutical
(Tokyo, Japan). Alendronate was purchased from LKT
laboratories Inc. (St. Paul, MN, USA). These reagents were
dissolved in phosphate-buffered saline (PBS; 0.05 M,
pH7.4), filtrated through Syringe Filters (0.45 μm; IWAKI
GLASS, Tokyo, Japan), and used for the various assays
described below.
Farnesol (FOH) and geranylgeraniol (GGOH) were pur-
chased from Sigma (St Louis, MO, USA). FOH and GGOH
were dissolved in dry ethanol. U0126 and LY294002 were
purchased from Promega (Southampton, Hants, UK) and
dissolved in DMSO. The dissolved reagents were re-
suspended in PBS (0.05 M, pH 7.4) and filtered through
syringe filters before use.Cell culture
We used C7 cells, which are mouse macrophage-like
cells that have the ability to differentiate into osteoclasts
[19,20]. The C7 cells were kindly provided by Dr. Shin-ichi
Hayashi (Tottori University, Japan) and cultured in α-
minimal essential medium (Sigma) supplemented with
10% fetal calf serum (Gibco, Carlsbad, CA), 50 ng/mL
human recombinant M-CSF (Leukoprol; Kyowa Hakko,
Shizuoka, Japan), 100 U/mL penicillin (Gibco) and
100 μg/mL streptomycin (Gibco), in an atmosphere
containing 5% CO2. RAW264.7 cells were purchased
from DS Pharma Biomedical (Osaka, Japan) and cul-
tured in α-MEM supplemented with 10% FCS, 100 μg/mL
penicillin, and 100 U/mL streptomycin in the presence of
5% CO2.Tartrate-resistant acid phosphatase (TRAP) staining
Cells were fixed with 10% formalin in PBS and were rinsed
with HEPES-buffered solution (0.9% NaCl, 10 mM
HEPES, pH 7.1). Cells were stained with Fast Red Violet
LB (Sigma) dissolved in TRAP buffer (50 mM sodium
acetate, 30 mM sodium tartrate, 0.1% Triton X-100,
100 μg naphthol AS-MX phosphate, pH 5.0) for 45 min at
37°C. Multinucleated osteoclasts were identified under
light microscopy as TRAP-positive cells with three or
more nuclei. The total number of TRAP-positive cells and
the number of nuclei in each well were determined.Cell viability
Cell viability was assessed by the tetrazolium-dye method
using a TetraColor ONE assay kit (WST-8 assay kit;
Seikagaku, Tokyo, Japan). C7 cells (5 × 104 cells/mL) were
plated in 96-well plates and incubated with various con-
centrations of minodronate or alendronate for 12 days.
Cultures were fed every three days by replacing with 50 μl
of fresh medium with or without various concentrations
of minodronate and alendronate. RAW264.7 cells (5 × 104
cells/mL) were plated in 96-well plates and incubated with
Figure 2 (See legend on next page.)
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Figure 2 Minodronate and alendronate inhibited osteoclast formation in RAW264.7 cells. (A, B) Determination of the appropriate
concentrations of minodronate (A) and alendronate (B) that are not cytotoxic to RAW264.7 cells. Cells (5000 cells/well) were incubated in 96-well
plates for 24 h and then treated with various concentrations of minodronate and alendronate. After 7 days, cell viability was quantified by
conducting WST-8 assays. The results are representative of 4 independent experiments. *P < 0.01 compared to the controls. (C-F) Inhibition of
osteoclast formation by minodronate and alendronate. RAW264.7 cells were cultured for 12 days and then treated with 1, 5, or 10 μM minodronate
(C, E) or 5, 10, or 20 μM alendronate (D, F). Cells were cultured in the presence of 50 ng/mL RANKL. Cultures were fed every 2 days by replacing with
500 μL of fresh medium, with or without minodronate, alendronate, and RANKL. Cultures were fixed and stained for TRAP-positive multinucleated cells
(C, D), and TRAP-positive cells (E, F) per well was counted. These results are representative of 4 independent experiments. *P< 0.01 compared to
50 ng/mL RANKL administration. (G, H) Inhibitory effect of minodronate and alendronate on RANKL and M-CSF-induced CTR and cathepsin K mRNA
expression. RAW264.7 cells were treated with minodronate (G) and alendronate (H) with 50 ng/mL RANKL for 7 days. Total RNA was extracted, and the
CTR and cathepsin K mRNA levels were determined by real-time PCR. The results are expressed as the ratio of treated to control samples after normalization
to GAPDH mRNA levels. The results are representative of 4 independent experiments. *P< 0.01 compared to 50 ng/mL RANKL administration.
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7 days. Cultures were fed every three days by replacing
with 50 μl of fresh medium with or without various con-
centrations of minodronate and alendronate. After both
time points, absorbance was measured at 492 nm with a
microplate reader (SK601, Seikagaku).
Quantitative real-time polymerase chain reaction (PCR)
Total RNA was isolated using RNAiso (Takara Biomedical;
Siga, Japan). One microgram of purified total RNA was
used for the real-time PCR analysis with the PrimeScript
RT reagent kit (Takara Biomedical). cDNA was subjected
to quantitative real-time PCR by using SYBR Premix Ex
Taq (Takara Biomedical) and the Thermal Cycler Dice
Real Time system (Takara Biomedical) in a 96-well plate
according to the manufacturer’s instructions. The PCR
conditions for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), calcitonin receptor (CTR), and cathepsin K
were 94°C for 2 min; followed by 40 cycles of 94°C for
0.5 min, 50°C for 0.5 min, and 72°C for 0.5 min. The fol-
lowing primers were used: CTR, 5′-CCA TTC CTG TAC
TTG GTT GGC-3′ (5′-primer) and 5′-AGC AAT CGA
CAA GGA GTG AC-3′ (3′-primer); cathepsin K, 5′-GGA
AGA AGA CTC ACC AGA AGC-3′ (5′-primer) and 5′-
GTC ATA TAG CCG CCT CCA CAG-3′ (3′-primer);
and GAPDH, 5′-ACT TTG TCA AGC TCA TTT-3′ (5′-
primer) and 5′-TGC AGC GAA CTT TAT TG-3′ (3′-pri-
mer). As an internal control for each sample, the GAPDH
gene was used for standardization. Cycle threshold (Ct)
values were established, and the relative difference in
expression from GAPDH expression was determined ac-
cording to the 2–ΔΔCt method of analysis and compared to
the expression in control cells.
Western blotting
C7 cells treated under various conditions were lysed
with lysis buffer (20 mM Tris/HCl, pH 8.0, 150 mM
NaCl, 2 mM EDTA, 100 mM NaF, 1% NP40, 1 μg/ml
leupeptin, 1 μg/ml antipain and 1 mM PMSF). The pro-
tein content of this cell lysate was determined using theBCA protein assay kit (Pierce, Rockford, IL, USA). An
aliquot of each extract (40 μg of protein) was fraction-
ated by electrophoresis in an SDS-polyacrylamide gel
and transferred to a polyvinylidene difluoride mem-
branes (Amersham, Arlington Heights, IL, USA). Mem-
branes were blocked with a solution containing 3% skim
milk, and then incubated overnight at 4°C with each of
the following antibodies: anti-phospho-extracellular sig-
nal-regulated kinase (ERK) 1/2 antibody, anti-phospho-
Akt antibody, anti-phospho-p38MAPK antibody, anti-
ERK1/2 antibody, anti-Akt antibody, and anti-
p38MAPK antibody (Cell Signaling Technology, Bev-
erly, MA, USA). Subsequently, the membranes were in-
cubated for 1 h at room temperature with anti-rabbit
IgG sheep antibody or anti-mouse IgG sheep antibody
coupled to horseradish peroxidase (Amersham). React-
ive proteins were visualized using a chemiluminescence
(ECL-plus) kit (Amersham) according to the manufac-
turer’s instructions.Statistical analysis
All results are expressed as means and S.D. of several
independent experiments. Multiple comparisons of the
data were performed by ANOVA with Dunnett’s test. P
values less than 5% were regarded as significant.Results
Cytotoxicity against C7 and RAW264.7 cells
The cytotoxic effects of minodronate and alendronate on
C7 cells were measured by WST-8 assay. The results
showed that minodronate did not affect cell viability at a
concentration of 0.1 μM to 0.5 μM for 12 days (Figure 1A).
We also found that alendronate did not affected cell
viability at a concentration of 0.5 μM to 2 μM for 12
days (Figure 1B). On the basis of these results, 0.1 to
0.5 μM were determined to be non-cytotoxic con-
centrations of minodronate, and 0.5 to 2 μM were
determined to be non-cytotoxic concentrations of
alendronate.
Figure 3 Minodronate and alendronate inhibited osteoclast formation via suppression of GGPP biosynthesis in C7 cells. C7 cells were
pretreated with 20 μM FOH or 20 μM GGOH for 4 h and were then treated with 0.5 μM minodronate or 2 μM alendronate and 25 ng/mL RANKL
plus 50 ng/mL M-CSF for 12 days. Cultures were fed every 3 days by replacing with 500 μL of fresh medium, with or without minodronate,
alendronate, RANKL, M-CSF, FOH, and GGOH. (A, B) Inhibitory effect of mevalonate pathway intermediates FOH or GGOH on the inhibition of
osteoclast formation by minodronate (A) and alendronate (B). Cultures were fixed and stained for TRAP-positive multinucleated cells, and the
number of cells per well was counted. These results are representative of 5 independent experiments. *P < 0.01 compared to 25 ng/mL RANKL
plus 50 ng/mL M-CSF administration. (C) CTR and cathepisin K mRNA expression in C7 cells that were treated with minodronate or alendronate
along with FOH or GGOH. Total RNA was extracted, and the CTR and cathepsin K mRNA levels were determined by real-time PCR. The results are
expressed as the ratio of treated to control samples after normalization to GAPDH mRNA levels. The results are representative of 4 independent
experiments. *P< 0.01 compared to 25 ng/mL RANKL plus 50 ng/mL M-CSF administration. (D, E) Cultures were fixed and stained for TRAP-positive
cells, and the number of cells per well was counted. These results are representative of 4 independent experiments. *P< 0.01 compared to 25 ng/mL
RANKL plus 50 ng/mL M-CSF administration.
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and alendronate on RAW264.7 cells. The results showed
that minodronate did not affect cell viability at a con-
centration of 1 μM to 10 μM for 7 days (Figure 2A). We
also found that alendronate did not affected cell viabilityat a concentration of 5 μM to 30 μM for 7 days (Figure 2B).
On the basis of these results, 1 to 10 μM were determined
to be non-cytotoxic concentrations of minodronate, and 5
to 30 μM were determined to be non-cytotoxic concentra-
tions of alendronate.
Figure 4 (See legend on next page.)
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Figure 4 Minodronate and alendronate inhibited osteoclast formation via suppression of GGPP biosynthesis in RAW264.7 cells.
RAW264.7 cells were pretreated with 20 μM FOH or 20 μM GGOH for 4 h and then treated with 10 μM minodronate or 30 μM alendronate, and
50 ng/mL RANKL for 7 days. Cultures were fed every 2 days by replacing with 500 μL of fresh medium, with or without minodronate,
alendronate, RANKL, FOH, and GGOH. (A, B) Inhibitory effect of mevalonate pathway intermediates FOH or GGOH on the inhibition of osteoclast
formation by minodronate (A) or alendronate (B). Cultures were fixed and stained for TRAP-positive multinucleated cells, and the number of cells
per well was counted. These results are representative of 5 independent experiments. *P < 0.01 compared to 50 ng/mL RANKL administration.
(C) CTR and cathepsin K mRNA expression in RAW264.7 cells that were treated with minodronate or alendronate along with FOH or GGOH. Total
RNA was extracted, and the CTR and cathepsin K mRNA levels were determined by real-time PCR. The results are expressed as the ratio of treated
to control samples after normalization to GAPDH mRNA levels. The results are representative of 4 independent experiments. *P < 0.01 compared
to 50 ng/mL RANKL administration. (D, E) Cultures were fixed and stained for TRAP-positive cells, and the number of cells per well was counted.
These results are representative of 4 independent experiments. *P < 0.01 compared to 50 ng/mL RANKL administration.
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formation through suppression of GGPP biosynthesis
We investigated the effect of minodronate and alendro-
nate on osteoclast formation in the presence of 25 ng/mL
RANKL plus 50 ng/mL M-CSF, with or without minodro-
nate and alendronate in C7 cells. C7 cells were seeded in
24-well plates (5000 cells/mL, 1 mL/well) in the presence
of 25 ng/mL RANKL plus 50 ng/mL M-CSF with or with-
out minodronate and alendronate. The culture medium
was replaced every 3 days. Generation of TRAP-positive
multinucleated cells increased in C7 cells in the presence
of 25 ng/mL RANKL plus 50 ng/mL M-CSF. On the
other hand, minodronate and alendronate inhibited
the generation of TRAP-positive multinucleated cells
in a concentration-dependent manner (Figure 1C, D).
We also investigated the effect of minodronate and
alendronate on the osteoclastogenesis process. Mino-
dronate and alendronate inhibited the cell fusion process
in a concentration-dependent manner (Figure 1E, F). In
addition, minodronate and alendronate inhibited the
RANKL- and M-CSF-induced mRNA expression of the
osteoclast markers CTR and cathepsin K (Figure 1G, H).
Next, we investigated whether minodronate and alen-
dronate suppress osteoclast formation in RAW264.7
cells. RAW264.7 cells were seeded in 24-well plates
(10,000 cells/mL, 1 mL/well) in the presence of 50 ng/mL
RANKL, with or without minodronate and alendronate.
The culture medium was replaced every 2 days. The
results showed that minodronate and alendronate inhibited
the RANKL-induced TRAP-positive multinucleated
cell formation and cell fusion process in a concentra-
tion-dependent manner (Figure 2C-F). In addition, mino-
dronate and alendronate inhibited the RANKL-induced
mRNA expression of CTR and cathepsin K (Figure 2G, H).
These results indicated that N-BPs suppressed osteoclast
formation through inhibition of cell fusion in osteoclast
precursor cells.
Previous studies have demonstrated that minodronate
and alendronate are capable of interfering with the
mevalonate pathway in many cell types, including osteo-
clastic cells. Minodronate inhibits the synthesis of FPP
or GGPP, two mevalonate pathway intermediates, and asa consequence, decreases prenylation of small GTPases
such as Ras and Rho [21-25]. Therefore, we next investi-
gated the possibility that minodronate and alendronate
inhibit osteoclast formation through suppression of FPP
or GGPP biosynthesis in C7 and RAW264.7 cells. Mino-
dronate and alendronate inhibited osteoclast formation,
whereas in combination with GGOH, generation of
TRAP-positive multinucleated cells, mRNA expression
of CTR and cathepsin K, and osteoclast nuclei numbers
were restored to the levels observed in the presence of
RANKL and M-CSF in C7 cells (Figure 3). By contrast,
co-treatment with FOH did not significantly reverse the
effects of minodronate and alendronate on osteoclast
formation. In addition, similar to osteoclast formation in
RAW264.7 cells, following the combination of GGOH
with minodronate or alendronate, generation of TRAP-
positive multinucleated cells, mRNA expression of CTR
and cathepsin K, and osteoclast nuclei numbers were re-
stored to the levels observed in the presence of RANKL
(Figure 4). This suggests that the inhibition of osteoclast
formation in C7 and RAW264.7 cells receiving N-BPs
was due to inhibition of GGPP biosynthesis.
Minodronate and alendronate inhibited RANKL- and
M-CSF-induced ERK1/2 and Akt activation in C7 cells
To investigate the molecular mechanisms of minodronate
and alendronate in C7 cells, we examined phosphorylated
ERK1/2, Akt and p38MAPK by Western blot analysis. An
increase in phosphorylation of ERK1/2, Akt, and p38MAPK
were observed 15–60 min after RANKL plus M-CSF
treatments (Figure 5A, G). We also observed that an in-
crease in phosphorylation of ERK1/2 was observed 1 day
after RANKL plus M-CSF treatments. In the phosphoryl-
ation of Akt, a consecutive increase was observed 1–10 days
after RANKL plus M-CSF treatment, compared to the
vehicle (PBS-treated). A substantial change in phosphory-
lated p38MAPK was not observed after RANKL plus
M-CSF treatments (Figure 5B, H).
The administration of minodronate and alendronate
did not lead to any increase in the phosphorylation of
ERK1/2 after RANKL plus M-CSF treatments. On the
contrary, this protein showed a decrease in
Figure 5 (See legend on next page.)
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Figure 5 RANKL plus M-CSF induced activation of ERK1/2 and Akt in C7 cells, which could be inhibited by minodronate and alendronate.
(A, B) C7 cells were cultured in the presence of 25 ng/mL RANKL plus 50 ng/mL M-CSF for 15, 30, and 60 min (A) or 1, 3, and 10 days (B). (C, D) C7
cells were treated with 0.5 μM minodronate for 24 h. Cells were cultured in the presence of 25 ng/mL RANKL plus 50 ng/mL M-CSF for 15, 30, and
60 min (C) or 1, 3, and 10 days (D). (E, F) C7 cells were treated with 2 μM alendronate for 24 h. Cells were cultured in the presence of 25 ng/mL
RANKL plus 50 ng/mL M-CSF for 15, 30, and 60 min (E) or 1, 3, and 10 days (F). Whole cell lysates were generated and immunoblotted with an
antibody against phosphorylated ERK1/2 (phospho-ERK1/2), phosphorylated Akt (phospho-Akt), phosphorylated p38MAPK (phospho-p38MAPK),
ERK1/2, Akt, and p38MAPK. (G–L) Quantification of the amount of phospho-ERK1/2, phospho-Akt, or phospho-p38MAPK normalized to the amount of
total ERK1/2, Akt, or p38MAPK, respectively. The results are representative of 5 independent experiments. *P < 0.01 compared to controls. (M) ERK1/2,
Akt, and p38MAPK activation in C7 cells, to which minodronate and alendronate were administered with or without the addition of GGOH. Phospho-
ERK1/2, phospho-Akt, phospho-p38MAPK, ERK1/2, Akt, and p38MAPK levels were determined by immunoblotting analysis of the whole cell lysate. (N)
Quantification of the amount of phospho-ERK1/2, phospho-Akt, or phospho-p38MAPK normalized to the amount of total ERK1/2, Akt, or p38MAPK,
respectively. The results are representative of 4 independent experiments. *P < 0.01 compared to controls.
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treatments. After administration of minodronate, there
was no consecutive increase in the phosphorylation of
Akt. However, minodronate and alendronate did not
inhibited the level of p38MAPK phosphorylation (Fig-
ure 5C, E, I, K). Moreover, we found that the administra-
tion of minodronate and alendronate decreased in
phosphorylation of ERK1/2 at 1–10 days after RANKL
plus M-CSF treatments. After administration of mino-
dronate, there was no consecutive increase in the phos-
phorylation of Akt, and a decrease from the vehicle level
was confirmed at 10 days after RANKL plus M-CSF
treatments. A change in phosphorylated p38MAPK in-
creased by minodronate administration after RANKL
plus M-CSF treatments (Figure 5D, F, J, L).
We also investigated whether administration of minodro-
nate or alendronate alone caused a change in phosphory-
lated ERK1/2, Akt, and p38MAPK. After administration of
minodronate or alendronate alone, phosphorylated ERK1/2
and Akt showed a sufficient decrease compared with that
of the vehicle (PBS-treated) from day 1 through day 10. A
change in phosphorylated p38MAPK increased by mino-
dronate or alendronate administration (data not shown).
We then administered minodronate or alendronate in
combination with GGOH to investigate whether the in-
hibition of ERK1/2 and Akt activation in C7 cells was due
to the inhibitory action of minodronate and alendronate
on GGPP biosynthesis via their mechanism of action.
Minodronate and alendronate inhibited the activation of
ERK1/2 and Akt, whereas in combination with GGOH,
the activation levels of these signal transduction molecules
were restored to the degree observed in RANKL and M-
CSF-treated cells (Figure 5M, N). These observations sug-
gest that the inhibition of ERK1/2 and Akt activation in
C7 cells treated with minodronate and alendronate was
due to the inhibition of GGPP biosynthesis.
Effects of U0126 and LY294002 administration on
osteoclast formation of C7 cells
It is suggested that osteoclast formation is inhibited in C7
cells by prevention of GGPP biosynthesis in themevalonate pathway, thereby blocking the signaling path-
way through the MEK/ERK and PI3K/Akt pathways.
Therefore, an attempt was made to confirm whether osteo-
clast formation was inhibited by inhibiting production of
ERK1/2 and Akt. U0126, a MEK1/2 inhibitor, and
LY294002, a PI3K inhibitor, were administered to C7 cells,
and their effect on osteoclast formation was examined.
U0126 and LY294002 inhibited osteoclast formation in a
concentration-dependent manner (Figure 6A, B). Adminis-
tration of U0126 showed a decrease in phosphorylated
ERK1/2 15–60 min and 1–10 days after RANKL plus
M-CSF treatments in a concentration-dependent man-
ner. Administration of LY294002 showed a decrease in
phosphorylated Akt 15–60 min and 1–10 days after
RANKL plus M-CSF treatments in a concentration-
dependent manner. U0126 (1 μM) or LY294002 (1 μM)
appeared to decrease production of phosphorylated
ERK1/2 or Akt to the same level as minodronate and alen-
dronate (Figure 5C-F, Figure 5I-L, Figure 6C-F). These re-
sults suggested that 1 μM U0126 or 1 μM LY294002
inhibited the phosphorylation of ERK1/2 or Akt to the
same degree as minodronate.
We next investigated whether a combination of 1 μM
U0126 and 1 μM LY294002 inhibited osteoclast forma-
tion in C7 cells to the same level as minodronate. The
combination of U0126 and LY294002 inhibited osteoclast
formation and number of TRAP-positive fused cells com-
pared with that of administration of U0126 or LY294002
alone. Moreover, the combinatorial effect of 1 μM U0126
and 1 μM LY294002 on osteoclast formation and number
of TRAP-positive fused cells declined to the same level as
minodronate and alendronate (Figure 7). These results
suggested that minodronate and alendronate inhibited
osteoclast formation through the suppression of ERK1/2
and Akt activation.
Discussion
In this study, we demonstrated that minodronate and
alendronate inhibit osteoclast formation through the sup-
pression of cell fusion induced by RANKL plus M-CSF or
RANKL in cultures of osteoclast precursor cells,
Figure 6 (See legend on next page.)
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Figure 6 U0126 (MEK1/2 inhibitor) or LY294002 (PI3K inhibitor) inhibited osteoclast formation. (A, B) C7 cells were treated with 0.25, 0.5, 1,
or 2.5 μM U0126 (A) or 0.5, 1, 2.5, or 5 μM LY294002 (B). Cells receiving U0126 or LY294002 were cultured in the presence of 25 ng/mL RANKL plus
50 ng/mL M-CSF. Cultures were fed every 3 days by replacing with 500 μL of fresh medium, with or without U0126, LY294002, RANKL, and M-CSF.
Cultures were fixed and stained for TRAP-positive multinucleated cells per well was counted. These results are representative of 5 independent
experiments. *P< 0.01 compared to 25 ng/mL RANKL plus 50 ng/mL M-CSF administration. (C, D) C7 cells were treated with 0.5, 1, or 2.5 μM U0126 or
1 or 5 μM LY294002 (D) for 24 h. Cells were cultured in the presence of 25 ng/mL RANKL plus 50 ng/mL M-CSF for 15, 30, and 60 min. (C) C7 cells
were treated with 0.5 μM minodronate for 24 h. Cells were cultured in the presence of 25 ng/mL RANKL plus 50 ng/mL M-CSF for 15, 30, and 60 min.
(E, F) Quantification of the amount of phospho-ERK1/2 or phospho-Akt normalized to the amount of total ERK1/2 or Akt, respectively. The results are
representative of 5 independent experiments. *P < 0.01 compared to controls. (G, H) C7 cells were treated with 0.5, 1, or 2.5 μM U0126 or 1 or 5 μM
LY294002 (D) for 24 h. Cells were cultured in the presence of 25 ng/mL RANKL plus 50 ng/mL M-CSF for 1, 3, and 10 days. (I, J) Quantification of the
amount of phospho-ERK1/2 or phospho-Akt normalized to the amount of total ERK1/2 or Akt, respectively. The results are representative of 5 i
ndependent experiments. *P < 0.01 compared to controls.
Figure 7 Combined effect of U0126 and LY294002 inhibited
the osteoclast formation. (A) C7 cells were treated with 1 μM U0126
and 1 μM LY294002 for 24 hours. Cells were cultured in the presence of
25 ng/mL RANKL plus 50 ng/mL M-CSF. Cultures were fed every 3 days
by replacing with 500 μL of fresh medium with or without minodronate,
alendronate, U0126, LY294002, RANKL, and M-CSF. Cultures were fixed
and stained for TRAP-positive multinucleated cells, and the number of
cells per well was counted. *P < 0.01, compared to 25 ng/mL RANKL plus
50 ng/mL M-CSF administration. #P < 0.01, compared to 1 μM U0126
administration. (B) Cultures were fixed and stained for TRAP-positive
cells, and the number of cells per well was counted. These results are
representative of 4 independent experiments. *P< 0.01 compared to
25 ng/mL RANKL plus 50 ng/mL M-CSF administration.
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hibition of GGPP biosynthesis. Coxon et al. reported that
a geranylgeranyl transferase inhibitor, but not a farnesyl
transferase inhibitor, inhibits the differentiation, function,
and survival of multinucleated osteoclasts in bone marrow
cultures [26]. These findings suggest that the geranylgera-
nyl small GTPs are important for the osteoclast
formation.
We observed that ERK1/2 and Akt were activated by
the treatment of RANKL plus M-CSF, whereas the activa-
tion was inhibited by the administration of minodronate
and alendronate. We also observed that U0126, a MEK1/2
inhibitor, and LY294002, a PI3K inhibitor, inhibited osteo-
clast formation in a concentration-dependent manner.
Furthermore, combined administration of 1 μM U0126
and 1 μM LY294002 inhibited osteoclast formation in C7
cells, as observed with minodronate and alendronate.
These results suggested that the MEK/ERK and PI3K/Akt
pathways are required for osteoclast formation, which is
also supported by the above-mentioned RANKL plus M-
CSF actions. These findings demonstrated that minodro-
nate and alendronate could inhibit osteoclast formation.
It was reported that RANK signaling activated tran-
scriptional factors through several signal transduction
pathways [27]. Among these factors, the activation of
those closely linked to osteoclast formation is regulated
by the MEK/ERK pathway. Downstream targets of
ERK1/2 induce and activate c-Fos, a transcription factor
for AP-1, which is essential for osteoclastogenesis [27].
Previous studies indicated that M-CSF stimulated ERK1/
2 activation in osteoclast precursor cells [28]. These
reported findings raise the possibility that ERK1/2 acti-
vation is necessary for osteoclast formation. Moreover,
we demonstrated that minodronate and alendronate in-
hibit osteoclast formation through suppression of ERK1/2
activation. These results suggest that minodronate and
alendronate are not only potentially useful as an anti-
resorptive agent for inhibiting osteoclast formation, but
also for inducing apoptosis in osteoclasts.
In the present study, we found that minodronate and
alendronate at lower concentrations of 0.25 and 1 μM or
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sion of cell fusion in C7 or RAW264.7 cells for 12 days
or 7 days, respectively. It has been reported that zolendro-
nate at a concentration of 30 μM for 3 days inhibited the
differentiation of osteoclast and osteoclast precursor cell
migration in RAW264.7 cells and in mouse bone marrow
cells [29]. In addition, various N-BPs were shown to in-
hibit osteoclast differentiation at a lower concentration of
0.1 μM in RAW264.7 cells for 6 days [30]. The inhibitory
effect of N-BPs on osteoclast formation at different con-
centrations may be due to treatment for different amounts
of time in osteoclast precursor cells. Collectively, these
findings suggest that N-BPs suppress osteoclast formation
via inhibition of cell fusion and migration.
Myeloma, breast, and lung cancer show osteolytic
changes in bone [31,32]. Osteolysis is an essential compo-
nent of the progression of every primary or metastatic
tumor in bone [31]. BPs have been reported to have direct
antitumor effects [14,18,22,23,25]. The antitumor activities
of BPs include induction of tumor apoptosis, inhibition of
tumor cell proliferation, decreased tumor cell adhesion,
and invasion into bone [33,34]. Minodronate has reported
to inhibit tumor cell metastasis in bone and to suppress
the metastasis-related bone destruction and osteoclast
activity [35-38]. In addition, alendronate reduced ongoing
and movement-evoked bone cancer pain, bone destruc-
tion, and the destruction of sensory nerve fibers that
innervate the bone [39]. Moreover, alendronate reduced
the formation of bone metastasis, and in addition to
paclitaxel, prevented the formation of bone metasta-
sis, non-osseous metastasis, and increased survival in
prostate cancer murine models [40]. These findings
suggest that minodronate and alendronate may suppress
cancer-related bone destruction via inhibition of osteoclast
formation, osteoclast activity, and tumor cell metastasis.Conclusion
In conclusion, we observed the inhibitory action of mino-
dronate and alendronate on osteoclast formation through
suppression of ERK1/2 and Akt activations in a macro-
phage-like cell line of C7 cells. This finding may indicate
the potential efficacy of minodronate and alendronate in
the therapy of metabolic bone diseases.Abbreviations
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